welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
FDA paves way for clinical trials of Sarepta’s Duchenne MD therapy SRP-5051
The U.S. Food and Drug Administration has taken a step that will allow Sarepta Therapeutics to start clinical trials of its Duchenne muscular dystrophy therapy SRP-5051.
That move was accepting the company’s Investigational New Drug application for SRP-5051. The therapy, known as a peptide phosphorodiamidate morpholino oligomer, is designed to treat those whose Duchenne MD stems from the exon 51 genetic mutation. They constitute the largest group of DMD patients — about 13 percent.
Genes are made up of dozens of components known as exons. A missing exon can lead to a gene mutation that generates a faulty protein, causing a disease.
rareRelated
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duc...The purpose of this study is to evaluate...
-
An open-label extension study for patients with Duchenne muscular dystrophy who participated in studies of SRP-5051The purpose of this extension study is t...
-
Local boy with Duchenne muscular dystrophy begins promising gene-targeted therapySeven-year-old Wyatt Hubbard was a bit t...
-
Can a drug cure genetic disease? | Steve Wilton | TEDxPerthhttps://youtu.be/qgfwOuvMLrE...
-
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017We issued an updated research report on ...
-
Exon Skipping Explained from Sarepta Therapeuticshttps://player.vimeo.com/video/238953537...
-
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, ran...BACKGROUND:Duchenne muscular dystrophy i...